The liver metastases treatment global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Liver Metastases Treatment Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size – The liver metastases treatment market size has grown strongly in recent years. It will grow from $1.45 billion in 2023 to $1.57 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to expansion of personalized medicine, expanded access to healthcare, enhanced multidisciplinary care, clinical trials and research initiatives.
The liver metastases treatment market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to patient-centric care models, precision medicine, shift towards outpatient, ambulatory care and regulatory initiatives. Major trends in the forecast period include next-generation sequencing technologies, immuno-oncology advancements, emergence of liquid biopsy technologies and adjuvant therapies.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/liver-metastases-treatment-global-market-report
Scope Of Liver Metastases Treatment Market
The Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Liver Metastases Treatment Market Overview
Market Drivers -The rising cases of liver disease are expected to propel the growth of the liver metastases treatment market going forward. Liver disease refers to any disorder of the liver that can stop the liver from working or prevent it from functioning well. Metastase treatments benefit overall wellness by protecting liver function, which is necessary for metabolism, detoxification, and other essential body activities. Moreover, in some situations, intensive treatments, including surgical resection, ablation, or targeted therapies, are needed for long-term remission, especially when paired with systemic medications such as chemotherapy or immunotherapy. For instance, in September 2022, according to Cancer Australia, an Australia-based government cancer agency, around 2,905 new cases of liver cancer were diagnosed in Australia in 2022 (2,113 males and 792 females). Further, the risk of developing liver cancer by age 85 is predicted to be 1 in 103 (or 0.97%) in 2022, 1 in 70, or 1.4%, for men, and 1 in 195, or 0.51%, for women. Therefore, the rising cases of liver disease are propelling the liver metastases treatment market.
Market Trends – Major companies operating in the liver metastases treatment market are focusing on introducing liver-directed therapies to offer effective and convenient treatments. Liver-directed therapies refer to medicines or interventions that directly target diseases or conditions affecting the liver. Liver-directed therapies help treat liver metastases by targeting cancerous cells specifically in the liver, either by directly destroying them or by cutting off their blood supply, using methods such as surgical resection, radiofrequency ablation, transarterial chemoembolization, radioembolization, and stereotactic body radiation therapy. For instance, in August 2023, Delcath Systems Incorporated, a US-based interventional oncology company, launched Hepzato kit, a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or limited extrahepatic disease amenable to resection or radiation. Hepzato kit is a combination product that administers melphalan, a chemotherapeutic agent, directly to the liver through Delcath’s Hepatic Delivery System (HDS), which allows higher drug exposure in target tissues while limiting systemic toxicity.
The liver metastases treatment market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Primary Cancer: Colorectal Cancer, Breast Cancer
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Get an inside scoop of the liver metastases treatment market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15849&type=smp
Regional Insights – North America was the largest region in the liver metastases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver metastases treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies – Major companies operating in the liver metastases treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol Myers Squibb, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Gilead Sciences Inc., Takeda Pharmaceutical Company, Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Ipsen, Seattle Genetics, Exelixis Inc., Array BioPharma Inc., Genentech Inc., Clovis Oncology, Agios Pharmaceuticals Inc., Taiho Pharmaceutical Co.Ltd
Table of Contents
1. Executive Summary
2. Liver Metastases Treatment Market Characteristics
3. Liver Metastases Treatment Market Trends And Strategies
4. Liver Metastases Treatment Market – Macro Economic Scenario
5. Global Liver Metastases Treatment Market Size and Growth
………………………..
32. Global Liver Metastases Treatment Market Competitive Benchmarking
33. Global Liver Metastases Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Liver Metastases Treatment Market
35. Liver Metastases Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
